Veracyte (VCYT) Tops Q3 EPS by 2c

Veracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $17.5 million versus the consensus estimate of $19.55 million.

“We delivered a solid performance this quarter in which we grew our genomic test volume, despite the impact of the hurricanes in key markets, further expanded reimbursement and booked our first Perceptarevenue,” said Bonnie Anderson, Veracyte\'s chairman and chief executive officer. “We believe our strong foundation to drive revenue growth is in place and we are encouraged by the increased momentum we began to see towards the end of the quarter. This included the increase in new Afirma Genomic Sequencing Classifier (GSC) accounts, adoption of Afirma GSC by Quest/Ameripath physicians and an expanded sales force in place.”

For earnings history and earnings-related data on Veracyte (VCYT) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Robinhood prices $2B convertible notes offering due 2029
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs